Skip to main content
Back to all tickers

VivoSim Labs, Inc. (VIVS) stock forecast & analysis

0.2608

NasdaqCM · USDDelayed by 15 minutes

Down: -0.0307, -10.5%

0.2428Down: -0.0180, -6.9%

1 analysis

Use Arrow keys to explore price history; Home and End jump to the oldest and newest points
Price history for VIVS.US from 10-23 12:00 to 11-21 00:59 with 1 analysis run marked; public runs are shown as stance-colored dots (Bullish, Bearish, or Neutral) and gated runs as a lock icon (sign in to read). Each marker is a link to sign in.BullishBearishNeutralLocked · sign in to read

Latest analysis: · verdict locked

Open
0.2800
Previous close
0.2915
Day range
0.2435 – 0.3808
52-week range
0.1200 – 3.40
Volume (shares)
147.19M
Net assets
Not available
Expense ratio
Not available
Shares outstanding
20.28M
P/E ratio
Not available
Dividend yield
0.00%
Beta
1.56
Market cap
5.29M
Market Scanner’s AI analysis of VivoSim Labs, Inc. (VIVS), updated November 2026: VivoSim Labs' recent coverage focused on a significant price spike driven by a commercial agreement and guidance raise, contrasted with a negative long-term technical trend.

This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of VivoSim Labs, Inc. (VIVS) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.

Summary

VivoSim Labs' recent coverage focused on a significant price spike driven by a commercial agreement and guidance raise, contrasted with a negative long-term technical trend.

Recent analyses for VivoSim Labs covered a dramatic single-session price increase on extremely high volume, which broke a six-week decline. This spike occurred alongside news of a seven-figure commercial agreement with a pharmaceutical company and a raise in fiscal 2027 revenue growth expectations. However, trend indicators and longer-term moving averages still point to a negative technical picture.

VIVS news & sentiment

News headlines focused on a significant commercial agreement and a raised revenue outlook, driving a sharp price increase. Social media discussion was not covered in the provided notes.

VIVS technical picture

A six-week decline was broken by a single session of extreme volume, pushing the price near its session high. However, trend indicators still point down, suggesting the one-day spike may not signal a sustained reversal.

Fundamentals

The company reported minimal trailing twelve months revenue and a significantly negative return on equity. Its market capitalization is small, and it does not pay a dividend.

Factors discussed — upside

  • Seven-figure commercial agreement with a top-10 pharmaceutical company announced.
  • Fiscal 2027 revenue growth expectations raised.
  • Single-session price increase of 142% on extreme volume.

Factors discussed — risks

  • Stock price remains significantly below its 200-day moving average.
  • Trend indicators still point down despite the recent price spike.
  • Negative trailing twelve months EPS and return on equity.
  • No specific value or term disclosed for the commercial agreement.
  • Technical price action
  • Commercial agreements
  • Revenue guidance
  • Valuation and returns

Summary updated .

VIVS technical indicators

Common technical indicators for VIVS, computed from its daily closing prices.

IndicatorValueReading
50-day simple moving average0.18Price above
10-day exponential moving average0.18Price above
Relative strength index (14-day)67.55Neutral
MACD line (12/26/9)0.0043Above its signal line
Bollinger bands (20-day, 2σ)0.07 – 0.24Price above the upper band

Analyses

Recent VIVS.US analyses are locked — sign in to read them or generate a fresh one.

CaseDescriptionDate

Frequently asked questions

What is the bull case for VivoSim Labs, Inc.?
The bull case centers on a recently announced seven-figure commercial agreement with a top-10 pharmaceutical company and an upward revision to fiscal 2027 revenue growth expectations. These developments followed a significant single-session price increase on extremely high volume.
What are the risks for VivoSim Labs, Inc.?
Risks discussed include the stock's price remaining well below its 200-day moving average and trend indicators still pointing downward despite the recent spike. Further concerns involve negative trailing twelve months earnings per share and return on equity, alongside a lack of specific disclosure regarding the commercial agreement's value and term.
Is VivoSim Labs, Inc. bullish or bearish?
Recent AI analyses of VivoSim Labs, Inc. examined factors on both sides. Discussed upside: The bull case centers on a recently announced seven-figure commercial agreement with a top-10 pharmaceutical company and an upward revision to fiscal 2027 revenue growth expectations. These developments followed a significant single-session price increase on extremely high volume. Discussed risks: Risks discussed include the stock's price remaining well below its 200-day moving average and trend indicators still pointing downward despite the recent spike. Further concerns involve negative trailing twelve months earnings per share and return on equity, alongside a lack of specific disclosure regarding the commercial agreement's value and term. These are descriptive observations, not a recommendation.
What is the latest sentiment on VivoSim Labs, Inc.?
News headlines focused on a significant commercial agreement and a raised revenue outlook, driving a sharp price increase. Social media discussion was not covered in the provided notes.
How does Market Scanner analyse VivoSim Labs, Inc.?
Every analysis of VivoSim Labs, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for VivoSim Labs, Inc.?

The bull case centers on a recently announced seven-figure commercial agreement with a top-10 pharmaceutical company and an upward revision to fiscal 2027 revenue growth expectations. These developments followed a significant single-session price increase on extremely high volume.

What are the risks for VivoSim Labs, Inc.?

Risks discussed include the stock's price remaining well below its 200-day moving average and trend indicators still pointing downward despite the recent spike. Further concerns involve negative trailing twelve months earnings per share and return on equity, alongside a lack of specific disclosure regarding the commercial agreement's value and term.

Is VivoSim Labs, Inc. bullish or bearish?

Recent AI analyses of VivoSim Labs, Inc. examined factors on both sides. Discussed upside: The bull case centers on a recently announced seven-figure commercial agreement with a top-10 pharmaceutical company and an upward revision to fiscal 2027 revenue growth expectations. These developments followed a significant single-session price increase on extremely high volume. Discussed risks: Risks discussed include the stock's price remaining well below its 200-day moving average and trend indicators still pointing downward despite the recent spike. Further concerns involve negative trailing twelve months earnings per share and return on equity, alongside a lack of specific disclosure regarding the commercial agreement's value and term. These are descriptive observations, not a recommendation.

What is the latest sentiment on VivoSim Labs, Inc.?

News headlines focused on a significant commercial agreement and a raised revenue outlook, driving a sharp price increase. Social media discussion was not covered in the provided notes.

How does Market Scanner analyse VivoSim Labs, Inc.?

Every analysis of VivoSim Labs, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.

Read the methodology

Bundles used
claude-medium-v2

Run a fresh VIVS.US analysis

Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.

Or read 1 earlier report



Most analyzed tickers